Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21988570 | 1.00 | GSR (0.53) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL15408570 | 0.98 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL15408573 | 0.98 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL1537309 | 0.94 | GSR (0.45) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8508994 | 0.93 | GSR (0.47) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8508254 | 0.93 | GSR (0.47) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8508705 | 0.92 | GSR (0.46) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8508905 | 0.92 | GSR (0.46) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8507421 | 0.92 | GSR (0.46) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8509066 | 0.90 | GSR (0.43) | GSRGNAI3GNAO1GNAI1RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115785950-A | Fluorescent probe for expansion-super-resolution microscopic imaging and expansion sample processing method | 浙江大学 | 2023-03-14 | — | — | CN | claimed |
| EP-3558920-B1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2021-04-07 | — | — | EP | claimed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| US-20070178219-A1 | Method for Reducing Acrylamide Formation | FRITO-LAY NORTH AMERICA, INC. | 2007-08-02 | — | — | US | claimed |
| US-5547983-A | Aromatic and polycyclic compounds and their use in human or veterinary medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-08-20 | — | — | US | claimed |
| EP-0250559-A1 | PARENTERAL NUTRITION THERAPY WITH AMINO ACIDS | VEECH, Richard L. (US) | 1988-01-07 | — | — | EP | claimed |
| WO-1987003806-A1 | PARENTERAL NUTRITION THERAPY WITH AMINO ACIDS | VEECH RICHARD L | 1987-07-02 | — | — | WO | claimed |
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| CN-117957258-A | Protease-mediated targeting-specific cytokine delivery using fusion polypeptides | 中外制药株式会社 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023131645-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| US-20230114464-A1 | Conditions Improving Poxvirus Stability | BAVARIAN NORDIC A/S (DK) | 2023-04-13 | — | — | US | disclosed |
| CN-115785950-A | Fluorescent probe for expansion-super-resolution microscopic imaging and expansion sample processing method | 浙江大学 | 2023-03-14 | — | — | CN | disclosed |
| EP-4117722-A1 | COMPOSITIONS IMPROVING POXVIRUS STABILITY | Bavarian Nordic A/S (DK) | 2023-01-18 | — | — | EP | disclosed |
| CN-1124442-A | Protein feed supplemented with dipeptide and tripeptide | UNIV KANSAS STATE (US) | 1996-06-12 | — | — | CN | disclosed |
| EP-0302175-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1989-02-08 | — | — | EP | disclosed |
| EP-0286898-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| EP-0285058-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0285057-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| US-3981772-A | Method of attenuating viruses with simultaneous stabilization of their antigens using selected aminomethylol compounds | POVERENNY ALEXANDR MIKHAILOVIC | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | CD47, FCGR1A, FCGR2A | GSR 3481/4885GNAI3 401/4885GNAO1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.